---
title: Cannabidiol and its Potential Evidence-Based Psychiatric Benefits - A Critical
  Review
date: '2024-01-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38267003/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240125170715&v=2.18.0
source: heidelberg[Affiliation]
description: The endocannabinoid system shows promise as a novel target for treating
  psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid, has
  been investigated in several psychiatric conditions, with diverse effects and an
  excellent safety profile compared to standard treatments. Even though the body of
  evidence from randomised clinical trials is growing, it remains relatively limited
  in most indications. This review comprises a comprehensive literature search to
  identify ...
disable_comments: true
---
The endocannabinoid system shows promise as a novel target for treating psychiatric conditions. Cannabidiol (CBD), a naturally occurring cannabinoid, has been investigated in several psychiatric conditions, with diverse effects and an excellent safety profile compared to standard treatments. Even though the body of evidence from randomised clinical trials is growing, it remains relatively limited in most indications. This review comprises a comprehensive literature search to identify ...